These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31198824)

  • 21. Evolution of innovation networks in industrial clusters and multidimensional proximity: A case of Chinese cultural clusters.
    Liu J; Fang Y; Chi Y
    Heliyon; 2022 Oct; 8(10):e10805. PubMed ID: 36247172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-regional Pharmaceutical Technology Transfer in China: Patterns and Proposed Investment Strategies.
    Ni J; Xu J; Hu Y; Su L; Wang Y
    Ther Innov Regul Sci; 2014 Mar; 48(2):226-235. PubMed ID: 30227501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can we predict firms' innovativeness? The identification of innovation performers in an Italian region through a supervised learning approach.
    Gandin I; Cozza C
    PLoS One; 2019; 14(6):e0218175. PubMed ID: 31185045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research on patent quality of Chinese listed traditional Chinese medicine enterprises from R&D investment perspective].
    Cao YD; Gong RJ; Chen N; Liu W
    Zhongguo Zhong Yao Za Zhi; 2019 Mar; 44(6):1284-1288. PubMed ID: 30989996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does efficiency influence firm investment size? Evidence from Ghana.
    Amoah B
    Heliyon; 2022 Aug; 8(8):e10281. PubMed ID: 36090231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry.
    Billette de Villemeur E; Versaevel B
    J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survey data on inter-firm linkages and innovation activities of Chinese manufacturing SMEs.
    Mei L; Zhang T; Chen J
    Data Brief; 2019 Dec; 27():104671. PubMed ID: 31720326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bi-objective game-theoretic model for collaboration formation between software development firms.
    Fahimullah M; Faheem Y; Ahmad N
    PLoS One; 2019; 14(7):e0219216. PubMed ID: 31291301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Firms navigating through innovation spaces: a conceptualization of how firms search and perceive technological, market and productive opportunities globally.
    McKelvey M
    J Evol Econ; 2016; 26(4):785-802. PubMed ID: 28163393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does factor endowment allocation improve technological innovation performance? An empirical study on the Yangtze River Delta region.
    Jianmin W; Li Y
    Sci Total Environ; 2020 May; 716():137107. PubMed ID: 32059322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Will Green CSR Enhance Innovation? A Perspective of Public Visibility and Firm Transparency.
    Wu W; Liu Y; Chin T; Zhu W
    Int J Environ Res Public Health; 2018 Feb; 15(2):. PubMed ID: 29401714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thoughts of the combination of medicine and engineering and collaborative innovation on surgery in China].
    Lyu ZJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jun; 23(6):562-565. PubMed ID: 32521975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovative Strategies for Talent Cultivation in New Ventures Under Higher Education.
    Liao S; Zhao C; Chen M; Yuan J; Zhou P
    Front Psychol; 2022; 13():843434. PubMed ID: 35432057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enterprise policy evaluation: is there a 'new' way of doing it?
    Lenihan H
    Eval Program Plann; 2011 Nov; 34(4):323-32. PubMed ID: 21665050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research on an evolutionary game model and simulation of a cluster innovation network based on fairness preference.
    Li C; Cao X; Chi M
    PLoS One; 2020; 15(1):e0226777. PubMed ID: 31929550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do cost-sharing and entry deregulation curb pharmaceutical innovation?
    Grossmann V
    J Health Econ; 2013 Sep; 32(5):881-94. PubMed ID: 23896384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovation to Immune: Empirical Evidence From COVID-19 Focused Enterprise Surveys.
    Khan K; Liu S; Xiong B; Zhang L; Li C
    Front Psychol; 2022; 13():850842. PubMed ID: 35432097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lens or Prism? Patent Citations as a Measure of Knowledge Flows from Public Research.
    Roach M; Cohen WM
    Manage Sci; 2013 Feb; 59(2):504-525. PubMed ID: 24470690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The innovation value chain of patents: Breakthrough in the patent commercialization trap in Chinese universities.
    Gong H; Nie L; Peng Y; Peng S; Liu Y
    PLoS One; 2020; 15(3):e0230805. PubMed ID: 32214371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of innovation in reducing South Korea's energy intensity: Regional-data evidence on various energy carriers.
    Hille E; Lambernd B
    J Environ Manage; 2020 May; 262():110293. PubMed ID: 32250783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.